Recorded device evidence

SafeSept® Transseptal Guidewire (SS-140) (K221707): indications, design and recorded evidence

The acquired K221707 file contains product-specific indications and users, design and operating principle, recorded comparison and differences, non-clinical evidence actually described sections. Compare these dated manufacturer statements with your own indication and design before commissioning evidence work. They describe this submission; they do not prescribe your testing, validate performance independently or establish a suitable predicate.

Evidence retrieved 2026-10-07. Source versions and topic-specific limits are listed below.

Computed exact-code research

This decision beside its recorded product-code cohort

The 2021–2025 complete-year cohort contains 5 selected decisions under primary code DRC. 5 have valid reported receipt/decision pairs; 0 pairs are missing or invalid.

No quartiles are displayed: this complete-year cohort has fewer than 20 valid pairs.

The table shows the named decision and up to four latest exact-code research records through 2026-09-27. It can include partial-year records outside the complete-year cohort. The quartiles above use the full stated cohort, not this displayed selection.

Research recordRecorded deviceReceipt → decisionCalendar elapsed daysRecorded submission type
K221707 ↗ · this pageSafeSept® Transseptal Guidewire (SS-140)2022-06-13 → 2022-09-1493Special
K240246 ↗Accusafe Transseptal Guidewire (GTR31180, GTR31230)2024-01-30 → 2024-07-26178Traditional
K241042 ↗SafeSharp Transseptal Needle (CLICK071, CLICK171, CLICK098, CLICK198)2024-04-17 → 2024-05-1730Special
K212625 ↗PathBuilder Transseptal Needle2021-08-18 → 2022-03-23217Traditional
K210328 ↗SafeSept Blunt Needle2021-02-04 → 2021-03-0529Special

Use this comparison: select a record to investigate, read its actual indications and design, and document differences. A shared code or elapsed period cannot establish its relevance to your device.

Calendar elapsed days are not active FDA review time, a promised schedule or a success probability. The selection includes only the stated recorded decisions, not all applications. Latest records can postdate the named historical decision and are contextual research, not its predicates. Shared codes, summaries and observed records do not prove equivalence, current market availability, buyer applicability or predicate suitability.

Calculation, selection and source versions

Reuse the complete-endpoint exact-primary-code, documented SE-decision cohort and its stated cutoff/window. Retain its type-7 quartiles only when at least 20 valid date pairs are present. Independently subtract the named official record’s receipt date from its decision date; missing or negative pairs remain unknown. Show up to four latest exact-code research records, excluding the named ID. Parent analysis hash, source snapshots and calculation versions are retained.

Calculation: fda-named-decision-cohort-context-1; cutoff 2026-09-27; 0 parent records excluded; units record counts; calendar elapsed days.

Source snapshots: 5a86994ba49a37e71e09be96803fd51981c6c43eaa96caab41aea2b188bfe002.

Read beyond the decision row

Recorded evidence and differences to investigate

The summary is manufacturer-submitted context hosted by FDA. Negative/no-study statements are preserved. Evidence themes are not binding legal requirements.

Short opening excerpts identify the source sections. Read the linked original for the full study context, negative statements, tables and limitations. Public quotations are limited to 120 words per acquired summary; the internal evidence packet retains exact section ranges for review.

Indications and users

K221707 · PDF page 3 ↗ Source 2

SafeSept@          is     indicated      for     use       in       procedures    where     access to      the         left   atrium     via the       transseptal
  technique       is desired.        The          SafeSept@     Transseptal       Guidewire         is     intended      for single    use       only.

Compare with your product: Compare the recorded indication, population, body site and use environment with your proposed label. Record each change instead of assuming the primary code settles intended use.

Design and operating principle

K221707 · PDF page 4 ↗ Source 3

The SafeSept® .018” Transseptal Guidewire is made of nitinol, a flexible memory wire material, device
that is 140cm in length.

The excerpt is shortened at a complete statement. Read the complete section in the original PDF before interpreting the evidence.

Compare with your product: Compare physical design, materials, energy, accessories and operating principle with your design. Ask which documented differences change the evidence scope.

Recorded comparison and differences

K221707 · PDF page 4 ↗ Source 3

The technological characteristics of this device are similar to the predicate device. There is no difference
between the two indications for use.

The excerpt is shortened at a complete statement. Read the complete section in the original PDF before interpreting the evidence.

Compare with your product: The summary’s comparison is a manufacturer statement about that submission. Investigate the actual design differences and cited records before considering any comparator or predicate.

Non-clinical evidence actually described

K221707 · PDF page 5 ↗ Source 4

For bench testing, dimensional and physical aspects of the device were inspected such as ‘J’ curve
dimensions, tip thickness, outer diameter, overall length, and proximal marking locations.

The excerpt is shortened at a complete statement. Read the complete section in the original PDF before interpreting the evidence.

Compare with your product: Treat these as documented evidence themes in this case, including any limitations or negative statements. Ask which protocols, design inputs and acceptance rationale would be justified for your product; these excerpts are not a mandatory test panel.

Extraction selection and limits

Select observed whole-line section headings or explicit colon-delimited inline labels on readable PDF pages, including the explicitly documented heading-spacing variants in this parser version. Preserve the original heading, character ranges and layout; do not repair excerpt text. Exclude letter boilerplate and uncertain pages. Stop at observed table headings; do not infer table columns or scalar results from layout text. Multi-column or suspicious split-numeric excerpts are excluded until reviewed alternate extraction is available. Original layout records remain retained; any alternate text has its own extractor-version locator and requires original-page review. For each dimension, prefer usable versioned alternate text where available, selecting its longest usable excerpt; otherwise select the longest usable original-layout excerpt. Ties preserve source order. Bounded to 64 PDF pages and 3,500 characters per section. This is a selection, not a complete dossier analysis.

Excluded extraction items: {}.

Known facts and deciding inputs

Known context: US. Confirm the organisation’s role, relevant activities and markets against the cited criteria.

Source factRecorded valueWhat to check
510(k) identifierK221707 [1]Dated official record fact; not proof of current commercial availability or applicability to another device.
Generic device categorySafeSept® Transseptal Guidewire (SS-140) [1]Dated official record fact; not proof of current commercial availability or applicability to another device.
Recorded applicantPressure Products Medical Device Manufacturing, LLC [1]Dated official record fact; not proof of current commercial availability or applicability to another device.
FDA product codeDRC [1]Dated official record fact; not proof of current commercial availability or applicability to another device.
Decision date2022-09-14 [1]Dated official record fact; not proof of current commercial availability or applicability to another device.
Recorded decision codeSESE [1]Dated official record fact; not proof of current commercial availability or applicability to another device.
Submission typeSpecial [1]Dated official record fact; not proof of current commercial availability or applicability to another device.
Receipt date2022-06-13 [1]Dated official record fact; not proof of current commercial availability or applicability to another device.

Prepare a differences and evidence worksheet

Use this checklist to gather your business or product details before speaking with a specialist. The items below explain what to record and suggest useful supporting documents. You can add your own answers in the editable project brief.

  1. Indications and users — what differs in our product?

    Compare the recorded indication, population, body site and use environment with your proposed label. Record each change instead of assuming the primary code settles intended use.

    Useful evidence: Our proposed indication, user/population and use environment beside this exact recorded indication.

  2. Design and operating principle — what differs in our product?

    Compare physical design, materials, energy, accessories and operating principle with your design. Ask which documented differences change the evidence scope.

    Useful evidence: Design description, materials/components, accessory list and a differences matrix.

  3. Recorded comparison and differences — what differs in our product?

    The summary’s comparison is a manufacturer statement about that submission. Investigate the actual design differences and cited records before considering any comparator or predicate.

    Useful evidence: Feature-by-feature differences and the underlying cited documents; no automated predicate selection.

  4. Non-clinical evidence actually described — what differs in our product?

    Treat these as documented evidence themes in this case, including any limitations or negative statements. Ask which protocols, design inputs and acceptance rationale would be justified for your product; these excerpts are not a mandatory test panel.

    Useful evidence: Existing protocols/results and design-specific evidence gaps, with standard editions and scope reviewed separately.

Work packages and dependencies

Questions for providers

Sources and data dates

Read the official document in context. The audit details identify the precise locators and preserved versions used for this page.

FDA openFDA — 510(k) decision records ↗

2026-10-05 · retrieved 2026-10-06

Audit details: precise locators and snapshot identifiers

Source key D01 · snapshot 5a86994ba49a37e71e09be96803fd51981c6c43eaa96caab41aea2b188bfe002

  • [1] device-510k-0001-of-0001.json:results[69509] · record d72fb061b09e0ca67a3d2bcb279c917f29a16eb60edf062b5bfb9f9719b53a53
  • [5] Complete results array / fda-decision-context:K221707 · record whole dataset partition

FDA 510(k) summary — K221707 ↗

Fri, 16 Sep 2022 04:00:06 GMT · retrieved 2026-10-07

Audit details: precise locators and snapshot identifiers

Source key D02 · snapshot 0a04ae713f4085bd9b5e3c0fed1e4d9900304d6540feaf98159aba4767bd974c

  • [2] PDF page 3 · record b944f9dc6ce253c455a0655ee135b630d37a6a0420b6090d49fa08a73653d2ca
  • [3] PDF page 4 · record 4ec098fbfe927a78758ccf3ba83795414888a52ffcd66f9b3ca71f0f9da18d9b
  • [4] PDF page 5 · record e2246e0ee06737515bcb93360ba7350016cc20b3de85764c340755a01f679c24

Prepare an editable project brief

Confirm the facts, scope and contact preference before sharing your project. Preparing this page sends no provider outreach.

Choose work packages to discuss

Compare FDA 510(k) Submission Services